Lisbon
,
Portugal
11 - 14 May 2024
European Society of Cardiology Heart Failure (ESC-HF 2024)
Presentation schedule and materials
The congress symposium is no longer available
Monday, 13 May 2024
ORAL PRESENTATION
Semaglutide 2.4 mg and NTproBNP in obesity-related HFpEF: insights from the STEP-HFpEF programme
Mark C. Petrie1; Barry A. Borlaug2; Javed Butler3; Melanie J. Davies4; Dalane W. Kitzman5; Sanjiv J. Shah6; Subodh Verma7; Thomas Jon Jensen8; Mette Nygaard Einfeldt8; Karoline Liisberg8; Mikhail N. Kosiborod9
MATERIALS AVAILABLE
ORAL PRESENTATION
Semaglutide and diuretic use in obesity-related HFpEF: Insights from the STEP-HFpEF programme
Kavita Sharma1; Sanjiv Shah2; Barry A. Borlaug3; Javed Butler4; Melanie J. Davies5; Dalane W. Kitzman6; Mark C. Petrie7; Subodh Verma8; Mette N. Einfeldt9; Thomas J. Jensen9; Søren Rasmussen9; Rabea Asleh10; Tuvia Ben-Gal11; Mikhail N. Kosiborod12 for the STEP-HFpEF Trial Committees and Investigators
MATERIALS AVAILABLE
Tuesday, 14 May 2024
ORAL PRESENTATION
Semaglutide and cardiovascular outcomes in patients with overweight or obesity and heart failure: A pre-specified analysis from the SELECT trial
John Deanfield1; Subodh Verma2; Benjamin Scirica3; Steven Kahn4; Scott Emerson5; Donna Ryan6; Ildiko Lingvay7; Helen Colhoun8; Jorge Plutzky9; Mikhail Kosiborod10; G. Kees Hovingh11,12; Søren Hardt-Lindberg11; Ofir Frenkel11; Peter E. Weeke11; Søren Rasumessen11; Assen Goudev13; Chim C. Lang14; Miguel Urina-Triana15; Mikko Pietilä16; A. Michael Lincoff17; On behalf of the SELECT investigator group
MATERIALS AVAILABLE
Keywords